Gold prices slip slightly after recent gains; U.S. data eyed
Investing.com - Harmony Bio (NASDAQ: HRMY) reported second quarter EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5M versus the consensus estimate of $204.59M.
Guidance
Harmony Bio sees FY 2025 revenue of $820.00M-$860.00M versus the analyst consensus of $843.60M.
Harmony Bio’s stock price closed at $35.54. It is up 4.25% in the last 3 months and up 8.25% in the last 12 months.
Harmony Bio saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Harmony Bio’s stock price’s past reactions to earnings here.
According to InvestingPro, Harmony Bio’s Financial Health score is "excellent performance".
Check out Harmony Bio’s recent earnings performance, and Harmony Bio’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar